Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis

References

• Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N. Engl. J. Med.354(9), 942–955 (2006).
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet372, 1502–1517 (2008).
   PubMed Web of Science ®Google Scholar
• Biogen Idec, Inc. Avonex® (IFNβ-1a) prescribing information. October (2008).
   Google Scholar
• Bayer HealthCare Pharmaceuticals, Inc. Betaseron® (IFN-β1b) prescribing information. April (2008).
   Google Scholar
• EMD Serono, Inc. Rebif® (IFN-β1a) prescribing information. December (2008).
   Google Scholar
• TEVA Pharmaceuticals USA, Inc. Copaxone® (glatiramer acetate) prescribing information. February (2009).
   Google Scholar
• Biogen Idec, Inc. Tysabri® (natalizumab) prescribing information. October (2008).
   Google Scholar
• Coles A. Multiple Sclerosis. In: Contemporary Treatments in Neurology. Scolding N (Ed.). Butterworth Heinemann, MA, USA, 130–146 (2001).
   Google Scholar
• EMD Serono, Inc. Novantrone® (mitoxantrone) prescribing information. August (2008).
   Google Scholar
• Treadaway K, Cutter G, Salter A et al. Factors that influence adherence with disease-modifying therapy in MS. J. Neurol.256, 568–76 (2009).
   PubMed Web of Science ®Google Scholar
• Moses H, Brandes D. Managing the adverse effects of disease-modifying agents used for the treatment of multiple sclerosis. Curr. Med. Res. Opin.24(9), 2679 (2008).
   PubMed Web of Science ®Google Scholar
• Frohman EM, Brannon K, Alexander S et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult. Scler.10(3), 302–307 (2004).
   PubMed Web of Science ®Google Scholar
• Galetta S, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs19(3), 239–252 (2005).
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology52, 1072–1074 (1999).
   PubMed Web of Science ®Google Scholar
• Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin. Ther.28(4), 461–474 (2006).
   PubMed Web of Science ®Google Scholar
• Linda H, von Heijne A, Major EO et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med.361(11), 1081–1087 (2009).
   PubMed Web of Science ®Google Scholar
• Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr. Opin. Neurol.22, 226–232 (2009).
   Google Scholar
• Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens35(3), 118–127 (1990).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol.253(1), 98–108 (2006).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol.46(3), 296–304 (1999).
   PubMed Web of Science ®Google Scholar
• Moreau T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet344, 298–301 (1994).
   PubMed Web of Science ®Google Scholar
• Ashton DS, Beddell CR, Cooper DJ et al. Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H. Anal. Chem.67(5), 835–842 (1995).
   PubMed Web of Science ®Google Scholar
• Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int. Immunol.7(1), 69–77 (1995).
   PubMed Web of Science ®Google Scholar
• Wing MG, Moreau T, Greenwood J et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest.98(12), 2819–2826 (1996).
   PubMed Web of Science ®Google Scholar
• Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology95(3), 427–436 (1998).
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain119(Pt 1), 225–237 (1996).
   PubMed Web of Science ®Google Scholar
• Tawara T, Hasegawa K, Sugiura Y et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J. Immunol.180(4), 2294–2298 (2008).
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner M, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology128(2), 260–270 (2009).
   PubMed Web of Science ®Google Scholar
• Mould DR, Baumann A, Kuhlmann J et al. Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br. J. Clin. Pharmacol.64(3), 278–291 (2007).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med.359(17), 1786–1801 (2008).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33, 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet354, 1691–1695 (1999).
   PubMed Web of Science ®Google Scholar
• Selma JK. Alemtuzumab significantly increases the proportion of clinically disease-free patients with relapsing remitting MS compared to subcutaneous interferon β-1a: results from a Phase 2 study. Mult. Scler.14(Suppl. 1), S5–S27 (2008). Presented at: World Congress on Treatment and Research in Multiple Sclerosis. Montreal, Canada, 17–20 September (2008).
   Google Scholar
• Vladic A. Early treatment of multiple sclerosis with alemtuzumab significantly improves patient functioning and self-reported quality of life compared to SC interferon β-1a. Mult. Scler.14, (P528) (2008). Presented at: World Congress on Treatment and Research in Multiple Sclerosis. Montreal, Canada, 17–20 September (2008).
   Google Scholar
• Fox E, Mayer L, Sullivan H, O’Donnell L, Melia K, Lake S. Two-year results with alemtuzumab in patients with active relapsing-remitting multiple sclerosis who have failed licensed β-interferon therapies. Mult. Scler.13, (P558) (2007). Presented at: 23rd Congress of the European Committee for Treatment of Research in Multiple Sclerosis. Prague, Czech Republic, 11–14 October (2007).
   Google Scholar
• Havrdova E. The CARE-MS I Trial (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis): design of a Phase 3, open-label, rater-blinded study of alemtuzumab in treatment-naive patients with relapsing MS. Neurology70, (P02.171) (2008). Presented at: 60th Annual Meeting of the American Academy of Neurology. IL, USA, 12–19 April (2008).
   Google Scholar
• Hutton G. The CARE-MS II Trial (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis): updated design of a Phase 3, open-label, rater-blinded study of alemtuzumab in patients with MS who have relapsed on therapy. J. Neur. Presented at: 19th Meeting of the European Neurological Society. Milan, Italy, 19–23 June (2009).
   Google Scholar
• Sullivan H and the CAMMS223 Study Group. ITP following treatment of multiple sclerosis patients with alemtuzumab in CAMMS223: case reports and risk management plan implementation. Neurology (Suppl. 1), A206 (2007). Presented at: 59th Annual Meeting of the American Academy of Neurology. MA, USA, 28 April – 5 May (2007).
   Google Scholar
• Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. Arthritis Rheum.44, 1977–1983 (2001).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood100, 768–773 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated with vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis.67(9), 1322–1327 (2008).
   PubMed Web of Science ®Google Scholar
• Gillard P, Huurman V, Van der Auwera B et al. Graves hyperthyroidism after stopping immunosuppressive therapy in Type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care32(10), 1817–1819 (2009).
   Google Scholar
• Sloka JS, Phillips PW, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J. Autoimmune Dis.2, 9 (2005).
   PubMedGoogle Scholar
• Munteis E, Segura N, Martinez J, Cuadrado E, Galvez A, Roquer J. Idiopathic thrombocytopenic purpura in patients with multiple sclerosis. Mult. Scler.12, S210 (2006).
   Google Scholar